Q3-osavuosiraportti
8 päivää sitten‧45 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
85 683
Myynti
Määrä
87 641
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 | - | - | ||
| 71 | - | - | ||
| 452 | - | - | ||
| 142 | - | - | ||
| 1 055 | - | - |
Ylin
186,35VWAP
Alin
181,35VaihtoMäärä
61,7 335 308
VWAP
Ylin
186,35Alin
181,35VaihtoMäärä
61,7 335 308
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 14.11. | |
| 2025 Q2-osavuosiraportti | 26.8. | |
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Yhtiökokous | 9.4. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
19 t sitten19 t sittenI present my extensive Bavarian Nordic analysis: Most investors still see Bavarian Nordic as "the monkeypox stock"—a volatile government contractor that booms during a crisis and busts when the panic fades. They are looking at the rear-view mirror. Based on the Q3 2025 data we just received and the trajectory of the last 12 months, my assessment is that this company has fundamentally changed its metabolism. It is no longer just a biodefense lumpy play; it is transitioning into a high-margin, commercial travel vaccine compounder. Here is my mechanistic breakdown of the situation. 1. The Financial Mechanism: "Peace" vs. "Panic" Revenue To understand Bavarian’s health, you must mechanically separate its two revenue engines. They operate with different physics. Engine A: Public Preparedness (The "Panic" Business) Product: Jynneos/Imvanex (Smallpox/Mpox). Mechanism: This is high-margin but lumpy. It relies on government stockpiling cycles. Current Status (2025): We have seen a stabilization here. Revenue for the first 9 months of 2025 was DKK 2.3 billion, exceeding the expected "base business" of DKK 1.5–2.0 billion. Insight: The market treats this revenue as low-quality because it’s unpredictable. However, the mechanism of endemic Mpox (Clade Ib) means governments are moving from "panic buying" to "strategic stockpiling." This raises the floor of this segment. Engine B: Travel Health (The "Peace" Business) Products: Rabipur/RabAvert (Rabies), Encepur (Tick-Borne Encephalitis), and the newly launched Vimkunya (Chikungunya). Mechanism: This is a volume-driven, recurring revenue model. It benefits from operating leverage—once the manufacturing fixed costs are covered, every additional dose sold drops almost purely to the bottom line. Current Status (2025): This is the real story. Travel Health revenue grew 23% in the first 9 months of 2025. This is not a fluke; it follows 22% growth in 2024. The Compounder: This segment is now generating ~DKK 2.75 billion annually. It is becoming the dominant engine, which deserves a higher valuation multiple than a government contractor. 2. The Catalyst: VIMKUNYA (Chikungunya Vaccine) Here is why the approval of Vimkunya (Feb 2025) is significant, beyond just "new revenue." The Biology: Vimkunya is a Virus-Like Particle (VLP) vaccine. Unlike live-attenuated vaccines (which use a weakened live virus), a VLP mimics the outer structure of the virus to trigger an immune response without containing the infectious genetic material. The Investment Implication: Because it is a VLP, it has a favorable safety profile, which allowed for approval in adolescents (12+) and faster market uptake. Commercial Launch: As of Q3 2025, we are seeing early sales (~DKK 75M). This is a "land grab" phase. Bavarian Nordic is leveraging its existing commercial infrastructure (sales reps already selling Rabies shots to travel clinics) to push Chikungunya. This is synergy in its purest form—selling a second product to the same customer with zero additional customer acquisition cost. 3. Valuation and Financial Health Let’s look at the numbers as of late November 2025. Market Cap: ~DKK 14.8 Billion. 2025 Revenue Guidance: ~DKK 6.0 Billion. Cash Position: Significantly bolstered by the sale of the Priority Review Voucher (PRV) for DKK 810 million (net income). The Multiple Discrepancy: If we normalize the earnings (stripping out the one-time PRV sale), the company is trading at roughly 8x to 9x EV/EBITDA. Biodefense companies often trade at 6–8x (due to risk). Commercial Vaccine players (like GSK or Sanofi’s vaccine units) often command 12–15x. The Trap: The market is pricing BAVA as if it’s still 2022 (biodefense only). The Reality: By the end of 2025, nearly 50% of revenue is coming from the high-growth commercial travel segment. The Thesis: Multiple Expansion: As the Travel Health segment overtakes Public Preparedness as the primary revenue driver, the stock will re-rate from a "contractor multiple" to a "pharma compounder multiple." Free Cash Flow Yield: With the completion of the tech transfers for Rabipur and Encepur (manufacturing moving in-house), margins will expand further in 2026. The Floor: The government biodefense business acts as a cash cow that funds the growth of the commercial business. It limits downside risk. Key Risks (The "Bear Case"): Execution Risk: If the Chikungunya launch stalls or competitors (like Valneva) capture significant share, the growth narrative breaks. Currency: They report in DKK but sell in USD/EUR. A strengthening DKK against USD hurts earnings. Part two ->·11 t sittenI miss the inclusion of the fact that the USA is facing a relatively imminent decision to scrap its strategic smallpox preparedness because the vaccines (130 million units) are expiring or to replace the stock with new vaccines. Here, Bavarian Nordic's freeze-dried version of Jynneos should be extremely well-positioned as a candidate, and if a rolling maintenance/replacement of 13 million vaccines annually (with 10 years shelf life) is agreed upon, then that should contribute around 650 million USD in annual revenue.
·3 päivää sittenShort d.13/11 - 0.75% Short d 19/11 - 1.45% Money is being bet on Bavarian's price to fall. Still think it's a shame that price 250 was not voted through.
·16 t sittenHonestly, the stock was up over 240 at one point. The cool-headed shareholder would have just taken the profit there. Especially after they had improved the offer, because they couldn't get through with the first offer. But some just had to squeeze the last drops out of the lemon. Gambled and lost. That's how it is. Dry your eyes.
·17.11.It's actually not that difficult. Previously, one could buy cheap and sell expensive. One can do that again. Bavarian is incredibly cheap, if they just stick to the plan and realize what they guide - on the low side. If one looks at the number of shareholders, quite a few have jumped ship on Nordnet, during the acquisition, but I wonder if we won't see investors who smell an opportunity.
·17.11.GSK Can anyone figure out if the last milestone payment to GSK has been booked, but will only be paid in the new year?·17.11.It should be. Since it's confirmed, an expense. Without me being an accountant, though.·18.11.It's a bit interesting that the company only has approx. 500 million in free cash flow over the first 9 months of the year. It was good that the voucher sale could be completed, otherwise it would have been a big fat zero. Is it in 2026 that the company gets full taxation? In round figures, that must result in an impact of approx. 200-225 million on the free cash flow.
·17.11.It looks like the buyers are returning. RSI very low, PE low, price target upgrades, ATP has to get involved = rising prices (unless the market crashes). Expect price 200 before year-end, but anything can happen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
8 päivää sitten‧45 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 19 t sitten19 t sittenI present my extensive Bavarian Nordic analysis: Most investors still see Bavarian Nordic as "the monkeypox stock"—a volatile government contractor that booms during a crisis and busts when the panic fades. They are looking at the rear-view mirror. Based on the Q3 2025 data we just received and the trajectory of the last 12 months, my assessment is that this company has fundamentally changed its metabolism. It is no longer just a biodefense lumpy play; it is transitioning into a high-margin, commercial travel vaccine compounder. Here is my mechanistic breakdown of the situation. 1. The Financial Mechanism: "Peace" vs. "Panic" Revenue To understand Bavarian’s health, you must mechanically separate its two revenue engines. They operate with different physics. Engine A: Public Preparedness (The "Panic" Business) Product: Jynneos/Imvanex (Smallpox/Mpox). Mechanism: This is high-margin but lumpy. It relies on government stockpiling cycles. Current Status (2025): We have seen a stabilization here. Revenue for the first 9 months of 2025 was DKK 2.3 billion, exceeding the expected "base business" of DKK 1.5–2.0 billion. Insight: The market treats this revenue as low-quality because it’s unpredictable. However, the mechanism of endemic Mpox (Clade Ib) means governments are moving from "panic buying" to "strategic stockpiling." This raises the floor of this segment. Engine B: Travel Health (The "Peace" Business) Products: Rabipur/RabAvert (Rabies), Encepur (Tick-Borne Encephalitis), and the newly launched Vimkunya (Chikungunya). Mechanism: This is a volume-driven, recurring revenue model. It benefits from operating leverage—once the manufacturing fixed costs are covered, every additional dose sold drops almost purely to the bottom line. Current Status (2025): This is the real story. Travel Health revenue grew 23% in the first 9 months of 2025. This is not a fluke; it follows 22% growth in 2024. The Compounder: This segment is now generating ~DKK 2.75 billion annually. It is becoming the dominant engine, which deserves a higher valuation multiple than a government contractor. 2. The Catalyst: VIMKUNYA (Chikungunya Vaccine) Here is why the approval of Vimkunya (Feb 2025) is significant, beyond just "new revenue." The Biology: Vimkunya is a Virus-Like Particle (VLP) vaccine. Unlike live-attenuated vaccines (which use a weakened live virus), a VLP mimics the outer structure of the virus to trigger an immune response without containing the infectious genetic material. The Investment Implication: Because it is a VLP, it has a favorable safety profile, which allowed for approval in adolescents (12+) and faster market uptake. Commercial Launch: As of Q3 2025, we are seeing early sales (~DKK 75M). This is a "land grab" phase. Bavarian Nordic is leveraging its existing commercial infrastructure (sales reps already selling Rabies shots to travel clinics) to push Chikungunya. This is synergy in its purest form—selling a second product to the same customer with zero additional customer acquisition cost. 3. Valuation and Financial Health Let’s look at the numbers as of late November 2025. Market Cap: ~DKK 14.8 Billion. 2025 Revenue Guidance: ~DKK 6.0 Billion. Cash Position: Significantly bolstered by the sale of the Priority Review Voucher (PRV) for DKK 810 million (net income). The Multiple Discrepancy: If we normalize the earnings (stripping out the one-time PRV sale), the company is trading at roughly 8x to 9x EV/EBITDA. Biodefense companies often trade at 6–8x (due to risk). Commercial Vaccine players (like GSK or Sanofi’s vaccine units) often command 12–15x. The Trap: The market is pricing BAVA as if it’s still 2022 (biodefense only). The Reality: By the end of 2025, nearly 50% of revenue is coming from the high-growth commercial travel segment. The Thesis: Multiple Expansion: As the Travel Health segment overtakes Public Preparedness as the primary revenue driver, the stock will re-rate from a "contractor multiple" to a "pharma compounder multiple." Free Cash Flow Yield: With the completion of the tech transfers for Rabipur and Encepur (manufacturing moving in-house), margins will expand further in 2026. The Floor: The government biodefense business acts as a cash cow that funds the growth of the commercial business. It limits downside risk. Key Risks (The "Bear Case"): Execution Risk: If the Chikungunya launch stalls or competitors (like Valneva) capture significant share, the growth narrative breaks. Currency: They report in DKK but sell in USD/EUR. A strengthening DKK against USD hurts earnings. Part two ->·11 t sittenI miss the inclusion of the fact that the USA is facing a relatively imminent decision to scrap its strategic smallpox preparedness because the vaccines (130 million units) are expiring or to replace the stock with new vaccines. Here, Bavarian Nordic's freeze-dried version of Jynneos should be extremely well-positioned as a candidate, and if a rolling maintenance/replacement of 13 million vaccines annually (with 10 years shelf life) is agreed upon, then that should contribute around 650 million USD in annual revenue.
- ·3 päivää sittenShort d.13/11 - 0.75% Short d 19/11 - 1.45% Money is being bet on Bavarian's price to fall. Still think it's a shame that price 250 was not voted through.·16 t sittenHonestly, the stock was up over 240 at one point. The cool-headed shareholder would have just taken the profit there. Especially after they had improved the offer, because they couldn't get through with the first offer. But some just had to squeeze the last drops out of the lemon. Gambled and lost. That's how it is. Dry your eyes.
- ·17.11.It's actually not that difficult. Previously, one could buy cheap and sell expensive. One can do that again. Bavarian is incredibly cheap, if they just stick to the plan and realize what they guide - on the low side. If one looks at the number of shareholders, quite a few have jumped ship on Nordnet, during the acquisition, but I wonder if we won't see investors who smell an opportunity.
- ·17.11.GSK Can anyone figure out if the last milestone payment to GSK has been booked, but will only be paid in the new year?·17.11.It should be. Since it's confirmed, an expense. Without me being an accountant, though.·18.11.It's a bit interesting that the company only has approx. 500 million in free cash flow over the first 9 months of the year. It was good that the voucher sale could be completed, otherwise it would have been a big fat zero. Is it in 2026 that the company gets full taxation? In round figures, that must result in an impact of approx. 200-225 million on the free cash flow.
- ·17.11.It looks like the buyers are returning. RSI very low, PE low, price target upgrades, ATP has to get involved = rising prices (unless the market crashes). Expect price 200 before year-end, but anything can happen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
85 683
Myynti
Määrä
87 641
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 | - | - | ||
| 71 | - | - | ||
| 452 | - | - | ||
| 142 | - | - | ||
| 1 055 | - | - |
Ylin
186,35VWAP
Alin
181,35VaihtoMäärä
61,7 335 308
VWAP
Ylin
186,35Alin
181,35VaihtoMäärä
61,7 335 308
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 14.11. | |
| 2025 Q2-osavuosiraportti | 26.8. | |
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Yhtiökokous | 9.4. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
8 päivää sitten‧45 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 14.11. | |
| 2025 Q2-osavuosiraportti | 26.8. | |
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Yhtiökokous | 9.4. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 19 t sitten19 t sittenI present my extensive Bavarian Nordic analysis: Most investors still see Bavarian Nordic as "the monkeypox stock"—a volatile government contractor that booms during a crisis and busts when the panic fades. They are looking at the rear-view mirror. Based on the Q3 2025 data we just received and the trajectory of the last 12 months, my assessment is that this company has fundamentally changed its metabolism. It is no longer just a biodefense lumpy play; it is transitioning into a high-margin, commercial travel vaccine compounder. Here is my mechanistic breakdown of the situation. 1. The Financial Mechanism: "Peace" vs. "Panic" Revenue To understand Bavarian’s health, you must mechanically separate its two revenue engines. They operate with different physics. Engine A: Public Preparedness (The "Panic" Business) Product: Jynneos/Imvanex (Smallpox/Mpox). Mechanism: This is high-margin but lumpy. It relies on government stockpiling cycles. Current Status (2025): We have seen a stabilization here. Revenue for the first 9 months of 2025 was DKK 2.3 billion, exceeding the expected "base business" of DKK 1.5–2.0 billion. Insight: The market treats this revenue as low-quality because it’s unpredictable. However, the mechanism of endemic Mpox (Clade Ib) means governments are moving from "panic buying" to "strategic stockpiling." This raises the floor of this segment. Engine B: Travel Health (The "Peace" Business) Products: Rabipur/RabAvert (Rabies), Encepur (Tick-Borne Encephalitis), and the newly launched Vimkunya (Chikungunya). Mechanism: This is a volume-driven, recurring revenue model. It benefits from operating leverage—once the manufacturing fixed costs are covered, every additional dose sold drops almost purely to the bottom line. Current Status (2025): This is the real story. Travel Health revenue grew 23% in the first 9 months of 2025. This is not a fluke; it follows 22% growth in 2024. The Compounder: This segment is now generating ~DKK 2.75 billion annually. It is becoming the dominant engine, which deserves a higher valuation multiple than a government contractor. 2. The Catalyst: VIMKUNYA (Chikungunya Vaccine) Here is why the approval of Vimkunya (Feb 2025) is significant, beyond just "new revenue." The Biology: Vimkunya is a Virus-Like Particle (VLP) vaccine. Unlike live-attenuated vaccines (which use a weakened live virus), a VLP mimics the outer structure of the virus to trigger an immune response without containing the infectious genetic material. The Investment Implication: Because it is a VLP, it has a favorable safety profile, which allowed for approval in adolescents (12+) and faster market uptake. Commercial Launch: As of Q3 2025, we are seeing early sales (~DKK 75M). This is a "land grab" phase. Bavarian Nordic is leveraging its existing commercial infrastructure (sales reps already selling Rabies shots to travel clinics) to push Chikungunya. This is synergy in its purest form—selling a second product to the same customer with zero additional customer acquisition cost. 3. Valuation and Financial Health Let’s look at the numbers as of late November 2025. Market Cap: ~DKK 14.8 Billion. 2025 Revenue Guidance: ~DKK 6.0 Billion. Cash Position: Significantly bolstered by the sale of the Priority Review Voucher (PRV) for DKK 810 million (net income). The Multiple Discrepancy: If we normalize the earnings (stripping out the one-time PRV sale), the company is trading at roughly 8x to 9x EV/EBITDA. Biodefense companies often trade at 6–8x (due to risk). Commercial Vaccine players (like GSK or Sanofi’s vaccine units) often command 12–15x. The Trap: The market is pricing BAVA as if it’s still 2022 (biodefense only). The Reality: By the end of 2025, nearly 50% of revenue is coming from the high-growth commercial travel segment. The Thesis: Multiple Expansion: As the Travel Health segment overtakes Public Preparedness as the primary revenue driver, the stock will re-rate from a "contractor multiple" to a "pharma compounder multiple." Free Cash Flow Yield: With the completion of the tech transfers for Rabipur and Encepur (manufacturing moving in-house), margins will expand further in 2026. The Floor: The government biodefense business acts as a cash cow that funds the growth of the commercial business. It limits downside risk. Key Risks (The "Bear Case"): Execution Risk: If the Chikungunya launch stalls or competitors (like Valneva) capture significant share, the growth narrative breaks. Currency: They report in DKK but sell in USD/EUR. A strengthening DKK against USD hurts earnings. Part two ->·11 t sittenI miss the inclusion of the fact that the USA is facing a relatively imminent decision to scrap its strategic smallpox preparedness because the vaccines (130 million units) are expiring or to replace the stock with new vaccines. Here, Bavarian Nordic's freeze-dried version of Jynneos should be extremely well-positioned as a candidate, and if a rolling maintenance/replacement of 13 million vaccines annually (with 10 years shelf life) is agreed upon, then that should contribute around 650 million USD in annual revenue.
- ·3 päivää sittenShort d.13/11 - 0.75% Short d 19/11 - 1.45% Money is being bet on Bavarian's price to fall. Still think it's a shame that price 250 was not voted through.·16 t sittenHonestly, the stock was up over 240 at one point. The cool-headed shareholder would have just taken the profit there. Especially after they had improved the offer, because they couldn't get through with the first offer. But some just had to squeeze the last drops out of the lemon. Gambled and lost. That's how it is. Dry your eyes.
- ·17.11.It's actually not that difficult. Previously, one could buy cheap and sell expensive. One can do that again. Bavarian is incredibly cheap, if they just stick to the plan and realize what they guide - on the low side. If one looks at the number of shareholders, quite a few have jumped ship on Nordnet, during the acquisition, but I wonder if we won't see investors who smell an opportunity.
- ·17.11.GSK Can anyone figure out if the last milestone payment to GSK has been booked, but will only be paid in the new year?·17.11.It should be. Since it's confirmed, an expense. Without me being an accountant, though.·18.11.It's a bit interesting that the company only has approx. 500 million in free cash flow over the first 9 months of the year. It was good that the voucher sale could be completed, otherwise it would have been a big fat zero. Is it in 2026 that the company gets full taxation? In round figures, that must result in an impact of approx. 200-225 million on the free cash flow.
- ·17.11.It looks like the buyers are returning. RSI very low, PE low, price target upgrades, ATP has to get involved = rising prices (unless the market crashes). Expect price 200 before year-end, but anything can happen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
85 683
Myynti
Määrä
87 641
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 | - | - | ||
| 71 | - | - | ||
| 452 | - | - | ||
| 142 | - | - | ||
| 1 055 | - | - |
Ylin
186,35VWAP
Alin
181,35VaihtoMäärä
61,7 335 308
VWAP
Ylin
186,35Alin
181,35VaihtoMäärä
61,7 335 308
Välittäjätilasto
Dataa ei löytynyt